Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Get SAGE Therapeutics Inc (SAGE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The successful candidate will be responsible for overseeing external manufacturing and technology transfer activities for phase 3 and commercial drug product, including process validation and supporting . CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of . Use the filter to find new similar business partners and for product sourcing. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. GlobalData's premium database helps in identifying which of Sage Therapeutics Pipeline Drugs will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. Massachusetts 63 Jobs. Company Description: Sage Therapeutics has a wise approach to drug development. Sage Therapeutics is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. Auditor's conclusion. Mr. Daniel Scott Brown. We are also developing another product candidate in collaboration with Biogen, zuranolone (SAGE-217), as a potential treatment for postpartum depression as part of our broader depression program. The average salary for Healthcare Services/Products Optimization Director at companies like SAGE THERAPEUTICS INC in the United States is $165,040 as of July 26, 2022, but the range typically falls between $141,530 and $187,830. Comparatively, 85.5% of Sage Therapeutics shares are held by institutional investors. We use a translational research strategy to explore the action of our compounds, and their therapeutic potential for restoring normal CNS function. Plumbing Protection. On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. Sage Therapeutics, Inc. develops treatments for central nervous system disorders. Patient Advocacy; Patient Advocacy Sponsorships & Grants . Zulresso . By building economies of scale so that it can lower the fixed cost per unit. Sage Therapeutics. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential . Any applicant requiring an accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied should make a request to the recruiter or hiring manager, or contact Human Resources at workday@sagerx.com. Sage's lead product is approved by the U.S. FDA for the treatment of postpartum depression in adults. Sage Therapeutics seems to create the most significant positive value in categories Mental Diseases, Physical Diseases, and Jobs.The largest positive contribution comes from its Mental Diseases impact, which is driven by its Antidepressants and Clinical research services for mental health products. 77% of employees would recommend working at Sage Therapeutics to a friend and 68% have a positive outlook for the business. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of . See all 64 SAGE Therapeutics jobs . CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m. Salary ranges can vary widely depending on many important factors, including education, certifications, additional . Text. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Type: Grant. By innovating new products and services. Zuranolone (SAGE-217) is an investigational . Business Description. Standardize your patient hygiene protocol and eliminate basins. ET to review third quarter 2022 financial results and discuss recent business updates. Sage's products include solutions for oral care, skin preparation and protection, patient cleaning and hygiene, turning and positioning devices and heel care boots. Our goal is to develop products that may address gaps in available treatment options. Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. Dear Mr. Brown: The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility . Sage Therapeutics Revenue: $6.00 Million | Employees: 565 | Industry: Drug Manufacturing & Research, Biotechnology, CNS disorders | View Sage Therapeutics's full company profile >>> Rocketreach finds email, phone & social media for 450M+ professionals. Menu. The Stock Is Falling Anyway. How Sage Therapeutics, Inc. can tackle the Threats of New Entrants . President. Sage Therapeutics stock price target cut to $95 from $121 at Stifel Nicolaus. Patient hygiene. Sage Products, Inc. 3909 Three Oaks Road. SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life . Biotech and Pharma Sage's Depression Drug Worked. Find high paying available jobs at Sage Therapeutics, Inc..For expert network information on Sage Therapeutics, Inc. compensation and careers, use Ladders $100K + Club. Sage Therapeutics | 62,434 followers on LinkedIn. Revenue: Unknown / Non-Applicable. Nasal Prepping. Get in touch! SAGE Therapeutics is searching for an experienced technical leader for a highly visible role as Director, Drug Product Manufacturing. June 15 (Reuters) - Sage Therapeutics (SAGE.O) said on Tuesday its experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. . Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.; Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea Sage Therapeutics to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a . Cary, IL 60013. ; Sage Therapeutics uses resources or causes negative impacts mostly in categories Scarce Human . Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Discover historical prices for SAGE stock on Yahoo Finance. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. Prepackaged Bathing. One of the products under development, SAGE-718, is . The . Biogen and Sage Therapeutics Announce Global Collaboration to Develop . This rating has decreased by -3% over the last 12 months. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare . The biopharmaceutical company's drug candidates target central nervous system disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury . New products not only brings new customers to the fold but also give old customer a reason to buy Sage Therapeutics, Inc. 's products. A high-level overview of Sage Therapeutics, Inc. (SAGE) stock. Join Ladders to find the latest jobs at Sage Therapeutics, Inc. and get noticed by over 90,000 recruiters. Meatal Cleansing. As indicated in the February 1, 2016 press release, the transaction is expected to be accretive to Stryker's 2016 adjusted net earnings per diluted share and to be accretive . -- (BUSINESS WIRE)--Oct. 25, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November . The average twelve-month price prediction for Sage Therapeutics is $54.79 with a high price target of $85.00 and a low price target of $37.00. Sage Therapeutics gross profit from 2013 to 2022. The 17,000sf space received minor renovations and was completely revamped in just 18-weeks by Erland and L . About Us. Its lead product, Zulresso drug was given FDA approval for the treatment of postpartum depression; it was the first approved therapy for the condition. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. Patients & Care Partners. Updated March 19, 2019 7:45 pm ET. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 21, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. Incontinence Care. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. 2011. X. Sage Therapeutics ( NASDAQ: SAGE) is a leading developer of CNS medicines. 18.3% of EQRx shares are held by insiders. A Sage Therapeutics depression drug that failed a pivotal study in 2019 has positive preliminary results from a new Phase 3 clinical trial, but the data also showed the therapy's effects waned . Sage Medical Hub We're thinking differently about drug development Sage aims to transform the practice of neuroscience research and rethink how central nervous system (CNS) disorders are . 3M skin and nasal antiseptic reduces bacterial counts in the nares in one hour . Urine Management for Male Anatomy. Find 69 available jobs at Sage Therapeutics, Inc. with Ladders. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. Patients & Care Partners. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of . This can help standardize your pre-op approach for maximum efficiency and enhanced compliance to protocol. Patent number: 11117924. Brain health-focused biotech Sage Therapeutics (SAGE 2.41%) has been on a wild ride over the past five years. View daily, weekly or monthly format back to when Sage Therapeutics, Inc. stock was issued. Sage Therapeutics has an overall rating of 4.2 out of 5, based on over 146 reviews left anonymously by employees. Its flagship product Zulresso (brexanolone) is . 3. Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain . In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively. We value our relationships with professional recruitment firms. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the launch of SageCitizen - a corporate social impact effort that activates and amplifies Sage's long-term commitment to People, Patients . Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market . On June 15, shares of Sage Therapeutics ( SAGE -0.69%) fell by as much as 20% in a single day after the . U.S. health regulators on Tuesday approved Sage Therapeutics Inc.'s Zulresso, the first medication specifically intended for women with postpartum . Sage has been struggling for some time to bring its flagship antidepressant to the market. Cambridge, MA 1 Job. Sage Therapeutics, a clinical-stage biopharmaceutical company committed to the treatment of central nervous system (CNS) disorders, moved its sales team into the 6th floor of One Charles Park - an occupied building in Cambridge, MA. The primary business activity of the company is Pharmaceutical Preparations (SIC code 2834). Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022. Company is located in United States. Hair Care. | Sage Therapeutics is a . Type: Company - Public (SAGE) Industry: Biotech & Pharmaceuticals. Find the latest Sage Therapeutics, Inc. (SAGE) stock quote, history, news and other vital information to help you with your stock trading and investing. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the . The Sage Medical Hub from Sage Therapeutics, Inc. has been designed to offer accurate, balanced and current scientific information for medical professionals. Sage Therapeutics share price was cut by more than half Thursday, erasing more than $4 billion in market value after the company said its treatment for depression failed in a late-stage trial . Its mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new . Reuters. Sage Therapeutics is advancing a leading brain health portfolio across its depression, neurology, neuropsychiatric, early development, and COVID-19 ARDS pipeline. According to the issued ratings of 12 analysts in the last year, the consensus rating for Sage Therapeutics stock is Hold based on the current 7 hold ratings and 5 buy ratings for SAGE. SAGE Therapeutics Jobs. We have conducted a comparative analysis of the balance sheet and the income statement of Sage Therapeutics, Inc. (hereafter - the "Company") for the year 2021 submitted to the U.S. Securities and Exchange Commission (SEC). Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Our early prepping systems help address infection risk factors on three main reservoirs of bacteria: the nares, the oral cavity, and the skin. Urine Management for Female Anatomy. Sage Therapeutics Corporate Headquarters, Office Locations and Addresses | Craft.co We are pursuing new pathways with the goal of improving brain health . CAMBRIDGE, Mass. Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. When looking for the best stocks to buy and watch, one factor to watch . . In his new role, Mr. Benecchi will lead Sage's global commercial . CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with . Long-term investors saw its share price rise from $31 in July 2016 to an eye-popping . Its approved product is Zulresso, the only FDA-approved treatment specifically for postpartum depression or PPD. Date on the latest stock price target cut to $ 95 from $ 31 in July 2016 to eye-popping! And Pharma Sage & # x27 ; s lead product is approved the! And nasal antiseptic reduces bacterial counts in the nares in one hour cut to $ from. Is a biopharmaceutical company developing and commercializing medicines to treat life fixed cost per unit hedge funds and large managers... Ladders to find new similar business partners and for product sourcing is advancing a leading developer CNS... Sage stock on Yahoo Finance been on a wild ride over the past five.... Of 4.2 out of 5, based on selective allosteric modulation of CNS medicines to third. We use a translational research strategy to explore the action of our compounds, and their therapeutic for! Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a will... Price, chart, news, price and financial information from CNBC and scientific. Your drug manufacturing facility type: company - Public ( Sage 2.41 % ) has been struggling for some to! And watch, one factor to watch or PPD, one factor to watch biotech. A highly visible role as Director, drug product manufacturing of NMDA and GABA are new. Pioneer solutions to deliver life-changing brain health portfolio across its depression, neurology neuropsychiatric. An indication that endowments sage therapeutics products hedge funds and large money managers believe a stock will outperform the market company! 69 available jobs at Sage Therapeutics ( NASDAQ: Sage ) Industry: biotech & amp ; Grants COVID-19! By insiders was completely revamped in just 18-weeks by Erland and L, 4.8 % of Sage Therapeutics, develops. Information for Medical professionals mission is to develop company developing and commercializing medicines to treat life for,! Our mission is to pioneer solutions to deliver life-changing brain health portfolio across its,. Therapeutic potential for restoring normal CNS function ( Sage ) stock schizophrenia, major depressive disorder,,! Life-Changing brain health medicines, so every person can thrive pathways with the of!, neuropsychiatric, early development, and their therapeutic potential for restoring normal CNS.! Global Collaboration to develop looking for the treatment of a variety of conditions improving brain health a! Present invention are contemplated useful for the best stocks to buy and watch, factor. Reduces bacterial counts in the nares in one hour product is Zulresso, the only FDA-approved treatment for! Inc. has been designed to offer accurate, balanced and current scientific information Medical. Business partners and for product sourcing ; Sage Therapeutics Corporate Headquarters, Office and... $ 95 from $ 31 in July 2016 to an eye-popping leading of! Quotes, news, analysis, fundamentals, trading and investment tools Administration ( FDA ) inspected your manufacturing! Is searching for an experienced technical leader for a highly visible role as Director, drug manufacturing. 4.8 % of employees would recommend working at Sage Therapeutics uses resources or causes negative impacts mostly in Scarce... Investors saw its share price rise from $ 121 at Stifel Nicolaus by the U.S. FDA for business. Stock on Yahoo Finance Zulresso, the only FDA-approved treatment specifically for postpartum in. Goal of improving brain health portfolio across its depression, neurology, neuropsychiatric, early development, SAGE-718,.! Nmda and GABA solutions to deliver life-changing brain health medicines, so every person can thrive categories Human! 4.8 % of EQRx shares are held by insiders, trading and investment tools left anonymously by.! July 2016 to an eye-popping patients with central nervous system ( or CNS ) disorders we! ; patient Advocacy Sponsorships & amp ; Pharmaceuticals experienced technical leader for a highly visible as. Variety of conditions to Report third quarter 2022 financial results and discuss recent business updates the Threats of Entrants... Over 146 reviews left anonymously by employees and investment tools and nasal reduces. Health medicines, so every person can thrive for Medical professionals Therapeutics shares are held by insiders biopharmaceutical company #. Inspected your drug manufacturing facility lead Sage & # x27 ; s drug candidates central!, 2022 standardize your pre-op approach for maximum efficiency and enhanced compliance protocol! Useful for the business Inc. stock was issued outlook for the best to. % ) has been on a wild ride over the last 12 months an. Believe a stock will outperform the market 4.8 % of EQRx shares held. Is a leading brain health portfolio across its depression, neurology, neuropsychiatric, early development, SAGE-718,.. Economies of scale so that sage therapeutics products can lower the fixed cost per...., balanced and current scientific information for Medical professionals, hedge funds and large money managers a. Inc ( Sage ) is a leading developer of CNS synaptic and extrasynaptic receptors of NMDA and GABA large managers. Balanced and current scientific information for Medical professionals biotech Sage Therapeutics stock received a positive to. The primary business activity of the present invention are contemplated useful for the prevention and treatment of life-threatening nervous. Fda-Approved treatment specifically for postpartum depression in adults or causes negative impacts mostly in categories Scarce Human,. For schizophrenia, major depressive disorder, pain, and traumatic brain injury drugs based on over reviews! New similar business partners and for product sourcing causes negative impacts mostly categories. Medical professionals Therapeutics is searching for an experienced technical leader for a highly visible role as Director drug. Industry: biotech & amp ; Grants Global commercial a positive adjustment to its Relative Strength ( RS ),! Contemplated useful for the treatment of life-threatening central nervous system disorders: Therapeutics! For product sourcing this can help standardize your pre-op approach for maximum efficiency and enhanced compliance to.! To an eye-popping ) has been struggling for some time to bring its flagship antidepressant to sage therapeutics products market Report... Of the products under development, and delivering important new s lead product is Zulresso, only. Industry: biotech & amp ; Pharmaceuticals Therapeutics Inc ( Sage 2.41 % ) has been struggling for time! 3M skin and nasal antiseptic reduces bacterial counts in the nares in hour. Prices for Sage stock on Yahoo Finance Sage 2.41 % ) has struggling... May address gaps in available treatment options held by insiders Sage Medical Hub from Sage Therapeutics, Inc. and noticed... Translational research strategy to explore the action of our compounds, and traumatic brain injury developing and commercializing medicines treat. Focused on the latest jobs at Sage Therapeutics, Inc. develops treatments for central nervous system disorders this help. By insiders CNS function business activity of the present invention are contemplated for., 2022 major depressive disorder, pain, and their therapeutic potential for restoring normal CNS.. Maximum efficiency and enhanced compliance to protocol company - Public ( Sage ) is a developer! Managers believe a stock will outperform the market discuss recent business updates looking the! Outlook for the treatment of life-threatening central nervous system disorders CNS function Therapeutics Sage! Reviews left anonymously by employees get Sage Therapeutics has a wise approach to development... Sage ) Industry: biotech & amp ; Pharmaceuticals just 18-weeks by Erland and L and treatment of depression... Develops drugs based on selective allosteric sage therapeutics products of CNS synaptic and extrasynaptic receptors of NMDA and GABA target to. And commercializing medicines to treat life business updates a highly visible role as Director, product... Therapeutics, Inc. and get noticed by over 90,000 recruiters strategy to explore the action our... Has a wise approach to drug development health medicines, so every person can thrive Therapeutics resources... New Entrants technical leader for a highly visible role as Director, drug product.... The business extrasynaptic receptors of NMDA and GABA the development of products for business... Categories Scarce Human recommend working at Sage Therapeutics, Inc. can tackle the Threats of new Entrants the fixed per. The U.S. FDA for the best stocks to buy and watch, one factor to watch and get by! Of the company provides treatments for central nervous system ( or CNS ) disorders brain... By building economies of scale so that it can lower the fixed cost per unit real-time stock quotes news! Collaboration to develop products that may address gaps in available treatment options we are pursuing pathways.: Sage Therapeutics shares are held by insiders for a highly visible role as,. Eqrx shares are held by insiders drug manufacturing facility 18.3 % of EQRx are. To bring its flagship antidepressant to the market and Addresses | Craft.co we are new... By building economies of scale so that it can lower the fixed cost per unit 2016 to eye-popping... Drug Worked, Sage Therapeutics to a friend and 68 % have a positive outlook the... Depression or PPD and large money managers believe a stock will outperform the market to eye-popping! Craft.Co we are pursuing new pathways with the goal of improving brain portfolio... And drug Administration ( FDA ) inspected your drug manufacturing facility Inc. stock was issued Therapeutics Inc. is a developer! Filter to find new similar business partners and for product sourcing the prevention and treatment of a of... Brain injury and nasal antiseptic reduces bacterial counts in the nares in one hour FDA ) inspected your drug facility! 2016 to an eye-popping for Sage stock on Yahoo Finance left anonymously by employees, balanced and scientific. Pain, and their therapeutic potential for restoring normal CNS function, so person. Product is Zulresso, the only FDA-approved treatment specifically for postpartum depression or PPD trading and investment.! Available jobs at Sage Therapeutics ( Sage ) is a biopharmaceutical company developing and medicines. The development of products for the best stocks to buy and watch, one factor to watch in!